Amgen (AMGN) PT Lowered to $288 at Cowen
Get Alerts AMGN Hot Sheet
Price: $285.11 -0.42%
Rating Summary:
20 Buy, 13 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
20 Buy, 13 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Cowen analyst Yaron Werber lowered the price target on Amgen (NASDAQ: AMGN) to $288.00 (from $294.00) while maintaining a Outperform rating.
The analyst commented, "Q4 EPS beat driven by other income as revs and OpEx were mainly in-line. Strength of Neulasta, Prolia, Repatha, Otezla and biosimilars drove modest rev upside. FY21 guidance reflects persistent COVID-19 headwinds and is largely in-line. We expect continued strong execution in Q1 despite seasonal weakness. We like risk/reward ahead of highly anticipated sotorasib combo data in H1:21 (likely ASCO)."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- Talen Energy Corp (TLNE) PT Raised to $120 at BWS Financial
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!